Hello Hive account@kafkanarchy84
These new vaccines have the potential to significantly reduce suffering and death from EV71 disease in China and in the future, the rest of the world. Nevertheless, manufacturing capacity and policy challenges remain for market entry and regulatory applications in other countries in the region with large populations of infants and children. Some questions remain: Will Chinese manufacturers make the vaccine available to other countries with EV71 outbreaks? Cross-protection of the vaccines against pandemic virus strains? How will they incorporate EV71 vaccine into the EPI? Can the vaccine be co-administered with other vaccines? How do you standardize the vaccine quality control and evaluation of EV71 vaccines? Having 2 vaccines against HFMD made in China is not only a milestone in the global vaccine field, but a testament to the hard work and innovation of the country’s scientific community and a boost to the local manufacturing sector.